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ABSTRACT 
Hyperglycaemia is prevalent in critical illness and increases the risk of further 
complications and mortality, while tight control can reduce mortality up to 43%. 
Adaptive control methods are capable of highly accurate, targeted blood glucose 
regulation using limited numbers of manual measurements due to patient discomfort 
and labour intensity. Therefore, the option to obtain greater data density using 
emerging continuous glucose sensing devices is attractive. However, the few such 
systems currently available can have errors in excess of 20-30%. In contrast, typical 
bedside testing kits have errors of approximately 7-10%. Despite greater measurement 
frequency larger errors significantly impact the resulting glucose and patient specific 
parameter estimates, and thus the control actions determined creating an important 
safety and performance issue. This paper models the impact of the Continuous 
Glucose Monitoring System (CGMS, Medtronic, Northridge, CA) on model-based 
parameter identification and glucose prediction. An integral-based fitting and filtering 
method is developed to reduce the effect of these errors. A noise model is developed 
based on CGMS data reported in the literature, and is slightly conservative with a 
mean Clarke Error Grid (CEG) correlation of R=0.81 (range: 0.68-0.88) as compared 
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to a reported value of R=0.82 in a critical care study. Using 17 virtual patient profiles 
developed from retrospective clinical data, this noise model was used to test the 
methods developed. Monte-Carlo simulation for each patient resulted in an average 
absolute one-hour glucose prediction error of 6.20% (range: 4.97-8.06%) with an 
average standard deviation per patient of 5.22% (range: 3.26-8.55%). Note that all the 
methods and results are generalisable to similar applications outside of critical care, 
such as less acute wards and eventually ambulatory individuals. Clinically, the results 
show one possible computational method for managing the larger errors encountered 
in emerging continuous blood glucose sensors, thus enabling their more effective use 
in clinical glucose regulation studies. 
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Identification 
 
 
INTRODUCTION 
 
Hyperglycaemia and high levels of insulin resistance are prevalent in critical care [1-
4]. Nutritional support regimes with a high carbohydrate content often compound the 
counter-regulatory response and do not suppress endogenous glucose production as 
normal [3,4]. Inhibiting the response to increased glycemic levels are factors such as 
increased insulin resistance, absolute or relative insulin deficiency, and drug therapy. 
Although hyperglycemia can be a marker of severity of illness, it can also worsen 
outcomes, leading to an increased risk of further complications such as severe 
infection [5], myocardial infarctions [1], polyneuropathy and multiple-organ failure 
3 
[2]. Tight glucose control has been shown to reduce ICU patient mortality by as much 
as 43% [2,6]. 
 
To better control glucose levels, model-based adaptive control methods [e.g. 7,13,18-
19] and sliding-scale protocols [e.g. 8] have been tested. Model-based methods can be 
very accurate, but require the ability to identify patient specific parameters and 
capture all of the observed dynamics. Chase et al [7] used a convex, computationally 
efficient integral-based formulation presented by Hann et al [9], which had the benefit 
of filtering the glucose errors encountered. However, that work used clinical data 
from GlucoCard bedside testing kits with an average error of 7-10%, whereas 
currently available emerging continuous glucose systems can have much larger errors 
for any given measurement. 
 
Chase et al [7] measured blood glucose every 30 minutes to achieve tight control. Due 
to the discomfort and labour intensity of such frequent measurement, emerging semi-
invasive continuous glucose sensors offer several advantages. In particular, they offer 
much higher data density, ranging from every 5 minutes to every 20 minutes [10-12], 
without any significant clinical effort. This higher data density could significantly 
improve the ability of model-based control methods to better fit patient specific 
parameters and more quickly react to sudden changes in patient condition.  
 
For example, Figure 1 shows a 24-hour critical care clinical trial using the adaptive 
control methods from Chase et al [7], but measuring only every hour. At ~180-200 
minutes the patient experienced a significant atrial fibrillation episode. Such episodes 
are preceded by a surge of counter-regulatory hormones, such as adrenaline, which is 
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identified by the controller at ~120 minutes as a major, sudden drop in modelled 
insulin sensitivity, SI. However, despite the relatively early warning, the controller 
could not react fast enough to fully prevent glucose levels from rising due, in part, to 
the relatively infrequent hourly measurement required for patient comfort and to 
minimise clinical labour.  
 
A much greater number of measurements, as might be obtained from emerging 
continuous glucose sensors, would provide the data to more readily identify, and react 
to, sudden changes in patient condition. Thus, more frequent measurement could be 
used to capture rapid changes in patient specific metabolic parameters. Identifying 
such parameters would enable accurate prediction of the impact of insulin or nutrition 
interventions, which is the critical element in any glycaemic control approach [7]. 
Hence, it is thus the sudden change in SI that this research aims to identify more 
rapidly and accurately using frequent measurement from emerging glucose sensors. 
The main requirement is enough accuracy to ensure accurate identification of the 
underlying modelled metabolic parameters that allow accurate model prediction of the 
affect of different clinical interventions. Therefore, this example is presented to 
illustrate the potential clinical control and patient benefits that could be obtained with 
frequent, accurate measurement. 
 
[Insert Figure 1 here] 
 
The Continuous Glucose Monitoring System (CGMS, Minimed, Northridge, CA) 
currently offers the greatest data density with little difference in error from other 
reported emerging sensor technologies, and has been approved for clinical use by the 
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FDA in the US [11,12].  While this technology is new, it has been evaluated in critical 
care [11], and been used for automated glucose regulation in critical care [13]. 
However, due in part to the errors and accuracy encountered, both reports were less 
than fully successful. CGMS sensors were also recently evaluated for glucose 
regulation in surgical units where the conclusion was that some technical and 
accuracy improvements were required before they could be regularly used to monitor 
strict glycaemic control [14].  
 
It is important to note that CGMS sensors have been initially developed as 
complementary measurement systems, rather than replacements for current glucose 
pin-stick methods [15], and are very effective at capturing trends and the impact of 
therapy changes. Current measurements of sensor error, such as the Clarke Error Grid 
(CEG) further illustrate this point [16]. The CEG is used to assess sensor accuracy by 
plotting the sensor measurement versus a gold-standard, usually laboratory, glucose 
measurement. The CEG also is broken into grids labelled A-D to assess the impact of 
the resulting sensor accuracy on the patient’s clinical treatment response [16], where 
the A and B zones are considered clinically accurate enough not to have significant 
negative impact on the likely clinical treatment response. However, the CEG 
assessment allows for larger errors of 20-30%, than might be desired for 
computational model parameter fitting and semi-automated, or automated, feedback 
control systems. 
 
The main advantage of automated, regular glucose measurements is their potential in 
tightly regulating blood glucose levels in treatment, both in hospital and for 
ambulatory individuals. Such automated solutions have been the topic of significant 
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recent discussion [e.g. 17-19], in part due to the emergence of sensors like the CGMS. 
These discussions primarily noted two things. First, that these automated sensors 
could be readily linked to a control loop as they remove manual clinical effort from 
the existing bedside glucose measurement process. Secondly, they noted that the 
measurements obtained were accurate enough to be potentially useful in clinical 
control situations [18-19]. Additionally, there has already been a study in a critical 
care unit [13], which represents a high acuity ward where automation might be most 
likely to first appear. The primary requirement is measurements with error low 
enough to minimise estimation errors that could bias clinical treatment decisions from 
an automatic controller.  
 
It is also important that any filtering or estimation based on a noisy measurement does 
not have significant time lag due to the method used. Minimising lag in the 
filtered/estimated glucose levels used in model-based control is critical in ensuring 
that subsequent glucose predictions are accurate. Without minimising lag, the 
modelled state for determining control action might not fully represent the actual 
state, leading to potentially unsafe clinical control actions and poor outcome. 
 
Therefore, this paper develops integral-based fitting and filtering methods to reduce 
the impact of larger errors and noise from these sensors. The goal is to produce a 
minimum lag estimate with good accuracy. The performance measure is expressed as 
mean absolute prediction error 1-hour ahead, and is used to assess the methods 
presented. This model prediction performance measure represents the fitted models 
ability to use the measured glucose data to accurately identify patient specific model 
parameters so that it can then be used to determine the affect of interventions, and 
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thus provide good control. Note that many similar semi-invasive sensors are emerging 
and have similarly wide ranges of potential error. To be clinically effective, 
particularly for glycaemic control applications, the larger errors that occur must be 
readily managed by consistent, programmable methods to take full advantage of the 
higher data density and lower clinical labour requirements returned by these sensors. 
 
METHODOLOGY 
 
A.  Physiology and System Model 
The system model employed has been presented and validated in Chase et al [7] and 
related clinical studies [20-22]. This model provides the basis for the filtering and 
fitting methods developed. 
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where G(t) = concentration of the plasma glucose above the equilibrium level 
(mmol/L), GE = equilibrium level of plasma glucose concentration (mmol/L), I(t) = 
concentration of the plasma insulin (mU/L), P(t) = exogenous glucose appearence rate 
(mmol/(L·min)), u(t) = insulin infusion rate (mU/min), Q(t) = interstitial insulin 
concentration (mU/L), I(t) = plasma insulin concentration (mU/L), VI = assumed 
insulin distribution volume (L), n = delay in interstitial transfer of insulin (min-1), pG = 
time-varying fractional clearance of plasma glucose at basal insulin (min-1), SI = time-
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varying insulin sensitivity (L/mU·min), k = parameter controlling the effective half 
life of insulin (min-1), αI = Michaelis-Menten parameter for insulin transport 
saturation, αG = Michaelis-Menten parameter for glucose clearance saturation. 
 
The model accounts for non-linear saturation of exogenous insulin disappearance rate 
from plasma (in Equation (3)) and its saturable utilisation to reduce blood glucose 
levels (in Equation (1)). The addition of transient insulin kinetics through interstitial 
boundaries via a convolution integral accounts for the dynamics seen in clinical trials 
[7], and better matches physiological knowledge. This model therefore effectively 
splits the glucose compartment into fast and slow compartments over a continuum 
rather than discrete states (e.g. [23]). Finally, significant exogenous insulin infusions, 
as typically encountered in hyperglycaemic critical care patients, effectively suppress 
endogenous insulin production [24], which is also modelled here as captured by the 
term pG for simplicity [7,9]. 
 
B.  Modeling Noise for the CGMS Sensor 
All the available literature reports CGMS accuracy and error referenced to laboratory 
standard measurements using a Clarke Error Grid. Hence, the exact distribution of the 
error is unknown. To add this error, an approximate model was created using the data 
available. Specifically, 78% of the measurements are within 20% of the actual value, 
defining the A range on the Clarke Error Grid [25], and the correlation between actual 
and the approximated blood glucose values is around 0.88 [11]. In addition, maximum 
errors in the literature are no greater than 40% based on observation of the results 
presented. These reported error values are also noted throughout the literature on 
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these sensors [12-20] and create an overall picture suitable for a simple, approximate 
model. 
 
Hence, the error can be simply and approximately modelled using a normal 
distribution with 17% (0.17) standard deviation. This standard deviation and 
distribution allows 78% of the measurements to be within 20%, matching the reported 
values of [11]. In addition, a limit of 40% (~2.5 standard deviations) was put in place 
to limit the peak error to match the reported data as observed in [10-20]. Thus, the 
overall model is quite simply a normally distributed random noise added to a 
simulated glucose value.  
 
Note that none of the references [10-20] provides specific statistical distributions or 
histograms to provide further insight, as all errors are primarily reported for this and 
similar sensors in terms of Clarke Error Grid performance. In addition, the Clarke 
Error Grid, while it does not show the resulting error distribution, is the current gold 
standard for reporting such sensor performance. Figure 2 shows a segment of a 
simulated patient glucose profile with “x” denoting the value with added CGMS error. 
Bands are shown for 20% and 40% error to show the size of the error that can occur 
using the resulting model. 
 
[Insert Figure 2 here] 
 
C.  Parameter Fitting and Identification 
The parameters (VI = 12 L, n = 0.16 min-1, k = 0.0099 min-1, αG = 0.04 L/mU, αI 
=0.0017 L/mU) are held constant at mean values found through an extensive literature 
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search [9,26]. The exogenous feed details, P(t), are known for each patient in this 
study, and would also be known for critical care enteral feeding regimes.  
 
The parameter identification method is integral-based similar to Hann et al [9] and 
identifies IS  as a time varying value, holding Gp  constant per the sensitivity study 
results from that research. In this research, the equilibrium glucose level, GE, is also 
identified as it can vary significantly as condition evolves. This approach identifies 
the major dynamics of hyperglycaemic patients, as primarily driven by insulin 
sensitivity, before secondary parameters are modified if required. Insulin sensitivity is 
the critical parameter as its effective value in this critical care model can evolve 
significantly over time with patient condition and drug therapy [3-4,7,9,21,26]. 
 
It is therefore important to ensure the fitting method for identifying time varying 
patient specific parameters is as low in computational effort as possible, so other 
parameters can be varied without significantly affecting the overall computation time.  
Computational time is a significant factor to consider in real time control, as well as in 
the process of refining and testing the model on large numbers of patients. 
 
The integral based method presented is developed as follows. First, integrating both 
sides of Equation (1) and defining )1( QQQ Gα+= , the following expression holds 
for any segment of time from t0 to t: 
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Substituting the total glucose level GT = (G+GE) into Equation (4) results in an 
equivalent expression that is easy to compute given measured total glucose levels: 
 
∫∫∫ +−−−=−
t
t
t
t
TI
t
t
ETGTT PdtdtQGSdtGGptGtG
000
)()()( 0  (5) 
 
To reduce computational complexity and account for a variation over time, the total 
time interval considered is divided into segments over which SI is piecewise constant. 
 
∑
=
− −−−=
N
i
iiiII ttHttHSS
1
)1(, ))()((  (6) 
 
where H(t - t0) is the Heaviside function defined H(t - t0) = 0 when t is less than t0, and 
H(t - t0) = 1, when t is greater than or equal to t0. Note that N in Equation (6) may be 
different depending on the number of hours used per segment. For this research, the 
glucose effectiveness, pG = 0.01, is held constant based on prior sensitivity analysis 
results [9]. The advantage of fixing pG is that the parameter GE can be included as an 
extra variable to be identified. This parameter is not easily measured in critical care 
and was approximated by moving averages in Hann et al [9].  
 
Using Equation (6), Equation (5) can be rewritten and expanded: 
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where the parameter GE is now a linear unknown variable along with the SI,i terms 
defining insulin sensitivity, and the integrals are evaluated over t0+60(j-1) < t < 
t0+60j and j = 1, …, N. However, these constants can be factored out after 
numerically integrating the data, resulting in a convex linear system of equations. 
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where the number of equations for each time segment can be arbitrarily selected by 
integrating over different time periods within that segment. To ensure solution values 
within physiologically valid ranges, weighted constraints are employed [7,9]. 
 
The convex least squares solution of Equation (8) defines the time-varying profile of 
SI for that time period. Using integrals, instead of derivative based fitting methods, has 
the advantage of being robust to noise in the measured glucose data, effectively 
providing a low-pass filter in the summations involved in numerically integrating the 
data. A full error analysis is contained in Hann et al [9] along with further details 
similar to both methods. 
 
D. Modified Method for CGMS 
In Chase et al [7] three GlucoCard glucose measurements are used with linear or 
higher order approximations to fit SI over sequential 1-hour periods during clinical 
glucose control trials. The GlucoCard is one example of several similar bedside 
13 
glucose test kits that use a pin-stick and capillary blood, or (if available [7]) arterial 
blood via a catheter, to obtain a sample that is manually inserted into a calibrated 
device via a test strip. It should be noted that in transient cases, such as after a meal, 
there can be up to 5-20 minutes of lag between whole blood measurements and the 
subcutaneous measurements from CGMS and similar sensors. In the context of this 
research, GlucoCard measurements assumed only 7% error and therefore did not 
overly bias approximated glucose curve used to fit SI. This limited effect is also partly 
due to the lower number of measurements, as only three (3) are available over the 1-
hour period, that could potentially significantly bias the results. Overall, the use of 
GlucoCard measurements at 30-60 minute intervals versus subcutaneous 
measurements with 5-20 minute lag at 5 minute intervals represents, qualitatively, an 
even to improved tradeoff for using the more frequent measurement. 
 
Figure 2 shows a glucose curve with CGMS noise approximated as defined. This 
curve shows the wide spread and larger errors that can be encountered with this type 
of sensor. If 13 measurements are available per hour (every 5 minutes) and 2-4 are 
significantly biased in one direction, then integrating over periods of up to 2 hours 
will not be long enough to average out their effect given the size of the potential 
errors of up to 20-30%. Hence, directly applying the methods of [9] for clinical 
adaptive glucose control, as in [7], may lead to inaccurate parameter identification. 
 
A solution to this problem is to use longer periods of data to perform the fitting, as 
well as smoothing the results of the parameter identification. The effect of a group of 
significantly biased measurements will then be effectively averaged over a longer 
period using integral methods, but without the lag introduced by long, higher order 
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filters. Thus, the methods of [7] can be reformulated for integrations across longer 
periods, with fixed base point t0 in Equation (4) for that period. This approach 
preserves the convex solution, global minimum and lower computational intensity of 
the overall approach. 
 
More specifically, a rolling 12-hour period is employed and the identified insulin 
sensitivity profile, SI(t), is smoothed to add additional filtering. The smoothing is 
defined as a modified moving average of the 12 hourly insulin sensitivity values 
determined every hour. 
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where jIS ,  is the identified insulin sensitivity parameter value for hour j = 1…12 
obtained from Equation (8), and j = 12 is the current time value of insulin sensitivity 
that is used to predict blood glucose variation over the next hour. The middle term of 
Equation (9) is a standard 3-point moving average and the end terms are designed to 
weight the end value the most, while reducing bias that can occur if an outlying 
measurement error occurs. 
 
This smoothing step is similar in concept to applying a second integration of Equation 
(5), but with specific weightings for the end values in the 12-hour window. To start 
the algorithm the initial periods during the first 12-hours are done the same way, but 
over the shorter time frame. As a result, there is a new prediction of SI each hour to 
15 
predict blood glucose levels in the subsequent hour. The overall process is shown in 
Figure 3 and has the following specific steps: 
 
• Obtain data over 12-hour window (less if starting) 
• Numerically integrate as in Equation (5) 
• Solve for SI(t) using Equation (8) 
• Smooth results with Equation (9) 
 
[Insert Figure 3 here] 
 
Note that while this method shares the same formulation as [9] it has three major 
differences. First, it extends the method to integrate over longer periods, in this case 
12 hours, with a fixed base point, and uses the added smoothing defined in Equation 
(9) to avoid the impact of outlying measurement errors to overly bias the fitted insulin 
sensitivity and subsequent glucose prediction. Second, it is designed to run forward in 
time, rather than retrospectively over an entire data set, as would be encountered in 
clinical glycaemic control applications. Finally, the use of an integral formulation 
over such a long time interval, versus very high order filters, ensures that no 
significant lag is added, except via the three point smoothing of Equation (9), without 
needing to use a model for the noise or the sensor dynamics. 
 
E. Patient Data and Selection Criteria 
To test this method, a random selection of 17 patients from a 201 patient data audit at 
Christchurch Hospital were selected [26]. Each patient record had a period greater 
than one day with intervals between measured data points of 3 hours or less. The data 
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density of three hours was selected to ensure enough measurements to enable a good 
model evaluation. The entire length of stay was not always considered, as many 
patients only had a shorter period of data that fitted the criteria. This subset broadly 
represents the cross section of patients seen in the ICU, regarding medical condition, 
age, sex, APACHE II scores and mortality, as summarised in Table I. Type 1 and 
Type 2 diabetes is somewhat over-represented because these patients are often more 
frequently measured. Note that BMI is not typically recorded in most ICU’s and was 
therefore not retrospectively available. Patients with serious head injury, morbid 
obesity, or who were moribund, were excluded. Ethical consent was obtained from 
the Canterbury Ethics Committee for this retrospective data analysis and research. 
 
F. Method Validation and Testing 
Each patient data set had already been fitted [9] and a time-varying SI(t) profile and 
approximated trajectory for GE were available. This data creates a virtual patient from 
which a glucose profile can be obtained using the retrospective feed and insulin 
infusion details, or other inputs as desired. Normally distributed CGMS sensor noise 
is added, as described, to the resulting virtual patient glucose profiles and the methods 
developed are then applied to identify SI and GE. These parameter values are then 
used in the model to predict subsequent blood glucose levels one hour later. The 
entire process mimics the control algorithm used in clinical adaptive control of 
glucose, such as presented in [7].  
 
Each patient profile was simulated N=20 times to test the algorithm and generate 
statistics on performance. Such, repeated Monte Carlo style simulation allows 
appropriate performance statistics to be generated. Thus, there are 17*20=340 
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simulations in total where each is different due to the use of random added noise 
given to each simulated glucose measurement. The outcome performance 
measurement is a comparison of the predicted blood glucose over the next hour and 
the simulated noise-free “true” value. Low mean absolute prediction error indicates 
successful filtering of the measurement error and accurate identification of the model-
based insulin sensitivity at that point in time. The overall goal is an analytical proof of 
concept test of the methods developed prior to clinical testing. 
 
RESULTS  
 
Figure 4 shows the Clarke Error Grid for a simulation of one of the 17 patients, and 
the correlation coefficient of R = 0.82 for all N=20 simulations. The results are 
visually comparable to those found in the literature and the correlation coefficient is 
slightly lower than reported values for critical care evaluation of 0.88 [11]. The only 
major difference to figures seen in the literature is the clear 40% maximum error 
limitation that is visible for the extreme points in Figure 4. Finally, note that each 
individual patient simulation yielded 500-2000 simulated measurements. Hence, the 
error grids, as shown in Figure 4, are primarily useful qualitatively due to the extreme 
number of points shown. 
 
Table II shows the correlation coefficients obtained from 7 patient profiles over N = 
20 simulations. The average correlation coefficient obtained for all 20 simulations 
over all 7 patients was 0.81 [range: 0.68-0.88]. Only 7 randomly selected patients, out 
of 17, were used to evaluate the noise model to validate the fundamental assumptions. 
The reason for using only 7 is that over 20 simulations of average 3 days length of 
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stay, each patient thus generates approximately 17,000 random simulated 
measurements, which is more than adequate for a simple validation of the assumed 
error model presented. Analysis of the remaining 10 patients did not change range or 
average values reported. 
 
[Insert Figure 4 here] 
 
The results in Figure 4 and Table II show that the simple, approximate error model 
employed is slightly conservative. More specifically, the correlation coefficients are 
approximately 8% lower and only the maximum was equal to that reported in the 
literature. These differences are likely due to the actual CGMS error distribution 
being slightly tighter than a true normal distribution as shown schematically in Figure 
5. Thus, more of the errors in the 20% band would be distributed closer to the mean 
value than the normal distribution allows. This result is further confirmed by the mean 
absolute relative difference (MARD) reported in CGMS trials of 13% [27] being 
slightly lower than the 17% standard deviation value used in the model.  
 
[Insert Figure 5 here] 
 
Overall, the simple, normally distributed error model proposed is a fairly close 
approximation to the limited clinical data reported. It also represents a conservative 
estimate of the error with respect to testing fitting and filtering methods by slightly 
overstating the magnitude of the errors that might be observed. Therefore, it is used 
for further analysis as is in this research. 
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Table III presents the mean one hour (forward) prediction errors for all 17 patients, 
where forward predictions were made every hour of the record after fitting the model 
parameters. The inputs used were the retrospective hospital record insulin and 
nutritional infusions. The standard deviation of those errors is reported to indicate the 
variance. Table III also includes the same results for the 10 patients similarly 
considered in Hann et al [9], where 30-minute GlucoCard measurements with 7% 
error were assumed. Comparing the results yields the impact of the greater number of 
measurements obtained with CGMS, the impact of its larger magnitude errors, and the 
impact of the methods presented to smooth the resulting glucose data so that accurate 
model fits and glucose response predictions are obtained. 
 
[Insert Table III here] 
 
Table III shows that the average error with the methods presented is 6.20%, which is 
effectively the same as the GlucoCard results. The standard deviations of that error of 
5.22% and 5.31% respectively, are also effectively identical. Hence, the methods 
presented are effective at providing predictive performance equal to that obtained 
with the lower error GlucoCard bedside testing kits which have been shown to yield 
good results in simulation [9] and in clinical control [7].  
 
More specifically, these results show that the filtering and resulting identification of 
patient specific metabolic parameters (SI) resulted in successful prediction by 
reducing the effect of the larger CGMS errors on fitting and prediction. These results 
are thus a comparison between the Monte Carlo simulated and filtered data, followed 
by identification and prediction, and the clinically recorded data and fitted value from 
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[9]. In particular, it should be noted that the modelled noise distribution used to 
approximate CGMS error is much wider than the resulting prediction noise, although 
both are normally distributed, indicating the overall efficacy of the methods presented 
through the steps of identification and control prediction. However, it should be noted 
that only dynamics within the model are captured in this proof of concept study and 
clinical testing where unmodelled dynamics may occur will be necessary. 
 
The worst case error however is much lower at 8.06% versus 10.90%, indicating more 
consistent performance and possibly the positive effect of greater numbers of 
measurements. For both sensors this worst case result occurs for Patient 554, 
indicating that this patient is equally difficult for both methods and that part of the 
worse results seen may be due to the model used for both cases not fully capturing 
this particular patient’s dynamics. For the best case, Patient 1090’s GlucoCard results 
are significantly better, showing that in this case, the lesser number, lower error 
measurement system still had an advantage. Finally, it is worth repeating that the 
average errors across the cohort were very similar, indicating that with the methods 
presented, both systems would likely have similar performance overall. 
 
An overall premise of this research is that directly using the methods of Hann et al [9] 
with a short window on CGMS data would result in potentially large prediction errors. 
Examining Patient 24 and applying the methods of [9] directly results in an average 
absolute prediction error of 18.25% with a standard deviation of 13.11%, indicating 
that a significant number of errors will be greater than 20-30%. These errors are large 
enough that clinically unsafe decisions might be taken by a controller. 
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In comparison, the methods presented resulted in an average absolute prediction error 
of 4.97% with standard deviation of 3.89%, which is 3-4 times lower. Note that 
approximating each hours worth of measurements with a linear line to reduce the 
effect of outliers, and then applying the methods of [9] directly, still results in an 
average absolute prediction error of 10.37% with standard deviation of 7.11%. This 
last result is still effectively 2 times larger than both the GlucoCard and current results 
presented for that patient. This example reinforces the overall concept that longer 
integration intervals, along with the smoothing method presented, are required to 
provide enough filtering to obtain prediction results with minimal lag that are suitable 
for clinical adaptive control applications. 
 
DISCUSSION 
 
The method presented uses the virtual patient data and extends the integral-based 
methods from Hann et al [9] to reduce the impact of noise in glucose prediction for 
clinical control applications similar to those in Chase et al [7]. Therefore, it represents 
only one way to manage this data and measurement error. Other approaches may 
provide equally good results. 
 
There is a large body of work on digital filtering that could be applied to this problem. 
While many digital filters can provide a clear, accurate signal from similarly noisy 
data, they can also introduce significant lag. More specifically, 4th to 8th order IIR 
filters have been successfully applied to this data. However, to obtain a similar ~7% 
accuracy in glucose value results in 30-40 minutes lag between predicted values and 
(simulated) true values. For clinical control applications in critical care, where patient 
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condition, insulin resistance and glucose levels can evolve rapidly over this time 
frame, this lag could prove unacceptably large for tight control. 
 
More complex filters based on Kalman or H-infinity theory may also be applicable. 
These approaches require, in the linear cases, a linear model of the system, which will 
not capture the range of dynamic behaviours seen in critical care that are necessary for 
providing tight control [7,13,20]. For non-linear methods a model is still required for 
which the validated system model presented may not be tractable for filter design. 
Recently, Knobbe and Buckingham [28] used non-linear Extended Kalman Filtering 
with CGMS and reference blood glucose data, and obtained a mean average deviation 
(MAD) of 9.6-16%, which is larger than the results presented. It should also be noted 
that this data was for ambulatory individuals and not critical care patients. However, 
such an approach could offer similar performance with a trade off of greater 
computational and design effort as model and filter complexity increases. 
 
Finally, the current CGMS monitor offers analysis software that can filter the data. 
However, this software uses windows up to 72 hours long to retrospectively fit the 
glucose data. In this research, the goal is to fit patient specific parameters, a process 
that is sensitive to large error or individual outliers, and then predict glucose 
accurately. Hence, the fitting methods used in that software are not necessarily 
directly applicable for a real-time application. 
 
The method presented proves very effective in reducing a typically non-linear, non-
convex optimization problem to a simple convex, linear system. All fitted values are 
within physiologically valid ranges reported in the literature. The integral method is 
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shown to be very fast and offers significant computational speed advantages over non-
linear approaches [9]. As presented, it also is computationally simple to implement. 
 
The mean average absolute prediction errors are effectively the same as values 
obtained using much more accurate bedside testing kits during clinical trials [7]. This 
result illustrates the potential of this method for control applications. It also shows 
that the method does not introduce lag into the process as large time lags would result 
in much larger errors given the potential rapid variability of patient glucose dynamics 
in critical care [e.g. 7,15]. Note that the interstitial fluid to capillary blood lag in 
glucose level for CGMS has been reported to be 4-5 minutes [29], which should not 
prove significant given the errors involved and the limited amount by which glucose 
might change over this timeframe. 
 
As a result, there is a significant potential clinical compromise between the 
advantages of integral-based methods in terms of computational cost, simplicity and 
convexity, and the clinical impact of the long 12-hour run-in period. Clinically, the 
impact is that for at least the first 8-10 hours of each sensor used poor results may be 
obtained. Given that device reported lifetimes are ~3 days approximately 1-2 sensors 
would be used per patient given average length of stays in many ICU studies of 3-5 
days. Thus, the run-in period thus represents, on average, about 15% of the sensor 
lifetime, a significant portion of time to be less useful. Finally, it is also currently not 
clear that sensor lifetimes will grow longer as time and technology move forward. 
Hence, it is currently a conservative expectation that there would be 1-2 such run-in 
periods to contend with for the average patient and ICU. 
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There are two possible clinical alternatives. First, an alternative method of control 
using bedside pin-stick based sensors could be used during this period. Such methods 
have recently been seen to be effective in critical care using hourly measurements 
[30,31]. A second approach would be to use other glycaemic control methods for the 
initial period, while overlapping the use of these sensors if possible during the run-in 
period on any following sensor use. Both approaches are obviously ad-hoc and other 
equally valid options may exist.  
 
Therefore, the run-in period can significantly impact clinical usage. The main 
question thus remains one of whether the added data obtained enhances the clinical 
results, via whatever methods used in glycaemic control, versus using other methods 
and sensors. This clinical decision will likely vary greatly on the specific unit or 
patient circumstances. Finally, none of this discussion deals with the potentially more 
clinically important, and somewhat related, issue of detecting and managing sudden 
sensor failure or loss of calibration. 
 
One limitation of this study is that measurements for these 17 subjects were primarily 
taken 2-3 hours apart, which can lead to dynamics being missed that could be 
captured with more frequent measurement. Such low measurement frequency may 
result in an “easier” problem for the methods presented. A second potential limitation 
of the overall analysis presented is that a model is used to both create and, via the 
methods presented, identify patient specific parameters, thus creating a situation 
where unmodelled dynamics do not exist outside the random error added. This 
problem is partly ameliorated by the prior clinical validation of the model and its 
reliance for the virtual patient profiles on measured clinical data.  
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A third limitation is that the study does not consider errors due to poor, or absent, 
calibration of the CGMS sensor. Clinically, in such cases, the data would have much 
larger error and may not fully represent reality, which is difficult to model. In 
particular, there are currently no rigorously reported failure rates or modes of failure 
for these or similar emerging sensors. Thus, it is not yet possible, without direct 
clinical experience perhaps, to reliably and accurately model this behaviour. More 
specifically, failure prediction is the prediction of a random event, which this model 
does not include for two reasons. First, it is not known or reported what the random 
failure rate might be, if any. Second, the affect of random failure would likely be 
handled separately, by a safely implemented system, from the measurement noise 
filter method presented in this research.  
 
For clinical control cases, such major failures or biased results would result in control 
algorithm failure, as the model would not be able to ascertain the patient’s metabolic 
state. Hence, such a sensor failure is of clinical concern, but outside the scope of this 
study. Therefore, further clinical testing will have to be undertaken to delineate these 
issues and fully prove the algorithm presented by clinical studies. Thus, this work 
should primarily be considered as a proof of concept study presented as foundation 
for further, safe clinical study. 
 
CONCLUSIONS 
 
Tight glycaemic control in critical care, or any other situation, requires accurate 
measurements to achieve the best results. Emerging continuous glucose sensors, such 
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as the Medtronic-Minimed CGMS device, offer significantly greater data density, and 
thus the potential for better control. However the measurements are subject to greater 
levels of inaccuracy than traditional pin-stick devices. This research presents a simple 
integral-based method for real-time control and filtering of glucose measurements 
with up to 40% added noise, using the CGMS device as a test case. While the analysis 
is based on critical care data, where glycaemic control is important, the methods 
presented can be readily generalised to applications outside critical care. 
 
A noise model is presented that conservatively represents the error reported for 
CGMS devices. This model is used to create several virtual patient glucose profiles 
using retrospective patient data. The profiles are used to test the filtering methods 
presented using Monte Carlo simulations to statistically assess the performance 
measured in terms of one-hour (forward) prediction error. This approach mimics the 
role such a system would play in adaptive glycaemic control in critical care. 
 
Overall results indicate that the methods presented achieve prediction errors of 6.2% 
+/- 5.2% on average with a range of 4.4-8.1% for the mean and 3.3-8.6% for the 
standard deviation. These results match or exceed the prediction performance 
obtained in a previous work for the same patient cohort using GlucoCard pin-stick 
sensors with 7-10% measurement error. Hence, the method presented is effective 
enough to show similar results to the current gold-standard for low-cost bedside 
glucose testing. Clinically, these results indicate that CGMS or similar emerging 
continuous glucose sensors have significant potential, in current form, to achieve 
tight, clinical glucose control.  
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TABLE I: Patient cohort and data 
 
Patient 
Number 
Medical 
Subgroup 
APACHE 
II Score Age Sex Mortality Diabetes 
24 Other Medical 25 47 M Y Type 1 
87 Other Medical 26 62 F   
130 Trauma 11 21 M  Type 1 
229 Cardiac 15 73 F   
289 Cardiac 18 70 M   
468 General Surgical 32 76 M   
484 Other Medical 34 30 F   
486 General Surgical 22 76 F  Type 2 
519 General Surgical 29 69 M  Type 2 
554 Other Medical 26 20 F  Type 1 
666 Cardiac 8 44 F  Type 2 
847 Other Medical 17 67 F   
1016 General Surgical 20 37 F  Type 2 
1025 Pulmonary 36 48 M  Type 2 
1090 General Surgical Unknown 37 F   
1099 Pulmonary Unknown 24 M Y  
1125 Other Medical Unknown 72 F Y  
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Table II: Correlation coefficients for 7 patients over N = 20 simulations 
Patient 
Number 
Correlation 
Coefficient 
24 0.68 
87 0.86 
130 0.85 
486 0.82 
519 0.75 
554 0.88 
1025 0.81 
Average 0.81 
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Table III: 1-hour forward glucose prediction error results where GlucoCard results are 
from Hann et al [9] for comparison. 
  Mean Prediction Error (%)
Error Standard Deviation 
(%) 
Patient GlucoCard 
Smoothed 
CGMS GlucoCard
Smoothed 
CGMS 
24 5.86 4.97 4.00 3.89 
87 4.71 5.03 5.21 4.08 
130 10.12 7.66 9.55 6.17 
229   5.85   5.17 
289   7.04   5.84 
468   6.31   4.96 
484   4.66   3.58 
486   7.88   7.44 
519 5.25 5.52 5.98 4.86 
554 10.90 8.06 8.89 8.55 
666 4.66 5.46 3.01 4.53 
847   7.43   5.44 
1016 7.01 6.14 6.27 5.36 
1025 5.09 6.27 4.54 6.25 
1090 1.86 4.37 0.87 3.26 
1099   6.97   5.13 
1125 6.83 5.71 4.78 4.19 
Average 6.23 6.20 5.31 5.22 
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Figure 1: Example of a 24-hour clinical trial result showing modelled and measured 
(x) glucose values and fitted insulin sensitivity, SI. Circled (o) data points show 
hourly glycaemic targets. The error bars for all cases show the 7% measurement error. 
The trial uses the adaptive control methods from Chase et al [7].
Time (mins) 
Drop in fitted patient specific 
insulin sensitivity at t = 120mins 
to a relatively much lower level
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Figure 2: Example of approximated CGMS error to a simulated glucose profile. 
Dashed lines show 20% and 40% bounds to estimate the magnitude of any error. 
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Figure 3: Identification and smoothing algorithm data window. 
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Figure 4: Clarke Error Grid for 1 of the 17 patient simulations, with R = 0.82 over all 
N=20 Monte Carlo simulations for that patient 
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Figure 5: Possible actual distribution versus normal approximated error distribution 
